Kallikrein-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Kallikrein-2 (KLK2; UniProt P20151), expressed in HEK293 cells. Suitable for serine protease activity assays, inhibitor IC50 determination, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-Kallikrein2

In stock

SKU
REC-Kallikrein2
$498.00

Target Overview

Kallikrein-2 (KLK2; UniProt P20151) is a 261-amino-acid serine protease of the glandular kallikrein family, encoded by the KLK2 gene on chromosome 19q13.4. The enzyme preferentially cleaves Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin, placing it within the tissue kallikrein–kinin system. This recombinant form is produced in HEK293 mammalian cells, a system that supports the post-translational processing — including signal-peptide cleavage and disulfide bond formation — required for proper folding of the trypsin-like catalytic domain. For researchers, the HEK293-expressed material offers a soluble, correctly folded enzyme suitable for direct use in fluorogenic or chromogenic substrate cleavage assays, without the refolding steps associated with prokaryotic expression. The active-site architecture (Ser-His-Asp catalytic triad) is preserved, making the preparation well-suited for small-molecule inhibitor IC50 determinations and kinetic characterisation (Km, kcat, kcat/Km) against synthetic peptide substrates. Because KLK2 protein is androgen-regulated and prostate-enriched, the recombinant is routinely used as a positive control in Western blot and immunohistochemistry assay development. Researchers validating anti-KLK2 antibodies — including Triple Point Biologics' matched antibody (RP-Kallikrein2) — use defined amounts of this recombinant to confirm band identity, titrate detection sensitivity, and establish linear signal range before proceeding to tissue-section work. The preparation is also applicable to substrate-identification experiments by mass spectrometry, where a defined enzyme source with known activity simplifies data interpretation.

Background

Kallikrein-2 is a member of the 15-gene human tissue kallikrein (KLK) family, all clustered at chromosome 19q13.4. Within the family, KLK2 and KLK3 (PSA) share the highest sequence identity (~80%) and are both transcriptionally driven by androgen receptor (AR) signalling through androgen response elements in their promoters. This AR-dependence has made KLK2 expression a useful molecular readout of AR pathway activity in prostate tissue, and its RNA levels have been characterised as a surrogate marker of AR activity in clinical specimens. McKay RR et al. (2026) performed detailed molecular characterisation of KLK2 RNA expression across prostate cancer subtypes, demonstrating that KLK2 transcript levels correlate with AR pathway engagement and vary with disease state — observations that rely on well-defined reference standards of the kind a recombinant protein provides for assay calibration (PMID: 41817312). Beyond its utility as a transcriptional readout, KLK2 protein exerts direct proteolytic activity relevant to the tumour microenvironment. The enzyme can activate pro-PSA (proPSA/KLK3) and has been implicated in processing of extracellular matrix components and growth factor precursors in prostate tissue. Lehner F et al. (2026) demonstrated that enzymatic blockage of kallikreins, including KLK2, inhibited growth and induced apoptosis in human prostate cancer cell lines, establishing the enzyme's catalytic activity as a functionally relevant research target for in-vitro mechanistic studies (PMID: 41531507). KLK2 expression is also studied in the context of androgen receptor signalling under castration-resistant conditions. Recombinant KLK2 protein supports these investigations by serving as an activity-positive control in cell-free assays or as an antigen for generating and validating detection reagents used in downstream tissue-based experiments. The androgen-regulated nature of the gene means that KLK2 immunohistochemistry, calibrated against this recombinant, can serve as a functional AR-activity reporter in tissue microarray studies. Researchers designing inhibitor screens targeting the kallikrein serine-protease active site use the recombinant to establish baseline enzymatic turnover rates before assessing compound-mediated inhibition. Triple Point Biologics has produced proteinase-focused research reagents since 1994; the matched anti-KLK2 antibody (RP-Kallikrein2), validated for Western blot, cross-references this recombinant for antibody validation workflows.

Applications

  • Fluorogenic substrate cleavage activity assay (e.g., Boc-Val-Pro-Arg-AMC or related kallikrein substrates)
  • Small-molecule inhibitor IC50 determination in a defined enzyme/substrate system
  • Positive control antigen for Western blot sensitivity titration and band-identity confirmation
  • Antigen standard for IHC antibody optimisation and signal-range calibration (pairs with RP-Kallikrein2)
  • Substrate identification by mass spectrometry using recombinant KLK2 as a defined enzyme source
  • Kinetic parameter determination (Km, kcat, kcat/Km) for peptide substrates
  • Pro-KLK3 (proPSA) activation assay to study kallikrein cascade processing
  • ELISA calibration standard for quantitative KLK2 detection in conditioned media or tissue lysates

References

  1. McKay RR et al. Molecular Characterization of KLK2 RNA Expression in Prostate Cancer. Clin Cancer Res. 2026. doi:10.1158/1078-0432.CCR-25-4293. PMID: 41817312.
  2. Lehner F et al. Inhibition of Growth and Induction of Apoptosis of Human Prostate Cancer Cells by Enzymatic Blockage of Kallikreins. Prostate Cancer. 2026. doi:10.1155/proc/7871208. PMID: 41531507.
  3. Ma K et al. Discovery of novel indole derivatives as LRH-1 antagonists for the treatment of castration resistant prostate cancer. Eur J Med Chem. 2026. doi:10.1016/j.ejmech.2026.118681. PMID: 41719800.
  4. Sharma S et al. Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly-Expressed, Combinatorial Therapeutic Target. Clin Cancer Res. 2026. doi:10.1158/1078-0432.CCR-26-0642. PMID: 42053993.
  5. Zacharski M et al. Transcriptional analysis reveals a markedly reduced expression of the voltage-dependent calcium channel α2δ1 subunit in canine prostate cancer compared to benign prostatic hyperplasia. BMC Vet Res. 2025. doi:10.1186/s12917-025-05046-7. PMID: 41068906.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma; tissue

Frequently Asked Questions

What molecular weight should I expect for recombinant Kallikrein-2 on SDS-PAGE or Western blot?

The mature recombinant KLK2 runs at approximately 28–30 kDa under reducing SDS-PAGE conditions, consistent with the processed form after signal-peptide cleavage from the 261-amino-acid precursor (UniProt P20151). HEK293 expression supports native N-glycosylation, so the observed band may migrate slightly higher than the calculated ~28 kDa depending on glycan load. Under non-reducing conditions, disulfide-stabilized dimers can appear near 55–60 kDa. Purity is >95% by SDS-PAGE; the dominant Coomassie band should be unambiguous at this position.

What processing form of KLK2 is this recombinant — pro-form or mature active enzyme?

This preparation is the mature, catalytically active form of KLK2, with the signal peptide and propeptide removed during HEK293-mediated secretion and processing. The trypsin-like catalytic domain is intact, and the Ser-His-Asp active-site triad is preserved. You do not need to activate this material with an exogenous protease before use. If your experiment specifically requires the zymogen (pro-KLK2) for activation studies, this product is not appropriate — the mature active enzyme is what is supplied.

What substrates does Kallikrein-2 cleave, and what fluorogenic substrate works best for activity assays?

KLK2 is a serine protease that preferentially cleaves Met-Lys and Arg-Ser bonds, releasing Lys-bradykinin from kininogen in vivo. For in vitro activity assays, the fluorogenic substrate H-D-Val-Leu-Arg-AMC (VLR-AMC) is well-characterized for KLK2 and gives a robust signal. Boc-Phe-Ser-Arg-AMC is an alternative with good selectivity. Chromogenic substrates such as H-D-Pro-Phe-Arg-pNA are also compatible. A starting enzyme concentration of 0.5–2 nM in assay buffer with 100–200 µM substrate is a reasonable starting point for Km determinations.

What assay buffer should I use for Kallikrein-2 activity assays, and is the storage buffer compatible?

For fluorogenic or chromogenic cleavage assays, use 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.01% Tween-20 as a starting condition — KLK2 shows good activity in this range. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is compatible with direct dilution into assay buffer; glycerol carry-over at typical working dilutions (≤1%) does not measurably inhibit activity. Avoid EDTA above 1 mM in the assay; KLK2 is a serine protease but trace metal chelation can affect substrate stability in some AMC-based systems.

What starting concentration of recombinant KLK2 is recommended for small-molecule inhibitor IC50 experiments?

For IC50 determinations, 1–5 nM recombinant KLK2 is a practical working range, keeping enzyme well below substrate Km to satisfy Morrison tight-binding or standard Cheng-Prusoff correction assumptions. Titrate your inhibitor across at least 8 concentrations spanning 3 log units bracketing the anticipated Ki. Run each inhibitor concentration against 100 µM VLR-AMC substrate in 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.01% Tween-20. Include a vehicle control (≤1% DMSO) to confirm solvent tolerance before full dose-response.

Can I use recombinant Kallikrein-2 as a positive control for Western blot with the matched rabbit polyclonal antibody?

Yes — this is one of the primary intended use cases. The matched antibody (SKU: RP-Kallikrein2) is validated for Western blot and was raised against KLK2, making it directly compatible with this recombinant as a positive control. Load 50–200 ng of recombinant KLK2 per lane on a 12% or 4–20% gradient gel; expect a clean band at ~28–30 kDa. This pairing is particularly useful for antibody validation experiments where a defined, structurally intact antigen is required alongside cell lysate lanes.

How much recombinant Kallikrein-2 should I load per lane to get a clean positive-control band on Western blot?

Load 50–200 ng per lane for a reliable signal using the matched RP-Kallikrein2 rabbit polyclonal antibody. At 50 ng, the band at ~28–30 kDa is detectable with standard HRP-conjugated secondary antibodies (1:5,000–1:10,000) and chemiluminescent detection. At 200 ng you get a strong reference band suitable for quantitative comparisons or if your detection system is less sensitive. Run the recombinant alongside cell or tissue lysates to confirm antibody specificity in your experimental system — see SKU RP-Kallikrein2 (/anti-kallikrein-2-rabbit-polyclonal-antibody) for validated dilution ranges.

How should I handle, dilute, and store recombinant Kallikrein-2 to preserve activity over time?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and should be stored at -20°C in single-use aliquots to avoid repeated freeze-thaw cycles, which progressively reduce serine protease activity. On the day of use, thaw on ice and dilute into your assay or storage buffer immediately before the experiment — do not leave the diluted enzyme at room temperature for extended periods. Working aliquots can be held at 4°C for up to 48 hours without significant activity loss. Endotoxin is <0.1 EU/µg by LAL, suitable for cell-based assays.

Validation imagery coming soon

Western blot validation figures for REC-Kallikrein2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →